



News Release

Suven Participating at 4th CNS Partnering & Deal Making Conference in USA

HYDERABAD, INDIA (Sept 22, 2011) – **Suven Life Sciences** is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets in CNS disorders for unmet medical needs covering potentially over \$30 billion market , today announced that it is participating at 4th CNS Partnering & Deal making Conference held at San Francisco from 22nd to 23rd Sep 2011.

CNS Partnering & Deal Making Conference is a CNS Diseases partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant CNS Disease issues and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about CNS Diseases business development trends, the CNS disease market, and novel technologies that shape up the industry.

Mr.Venkat Jasti CEO of Suven is scheduled to discuss the company's corporate overview, business strategy and partnering activity by presenting their Phase 2 ready clinical candidate **SUVN-502 for cognition in Alzheimer's and Schizophrenia and other pipeline compounds** at this Partnering & Deal making conference where the world's top notch investment professionals will present along with the most innovative companies who are decision makers.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. **The Company has twelve (12) internally-discovered therapeutic drug candidates** currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to **developmental candidate SUVN-502** for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.